NBIX
Neurocrine Biosciences Inc.
Latest News for NBIX
BMO Capital analyst Evan Seigerman maintained a Hold rating on Neurocrine today and set a price target of $147.00. The company’s shares opened toda......
In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Buy rating on Neurocrine, with a price target of $200.00. The company’s......
Neurocrine Biosciences (($NBIX)) announced an update on their ongoing clinical study. Neurocrine Biosciences has recently completed a Phase 2 clini......
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Neurocrine, with a price target of $168.00. The company’s s......
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cogent Biosciences (COGT – Research Report) and Neur......
Mizuho Securities analyst Uy Ear maintained a Hold rating on Neurocrine yesterday and set a price target of $146.00. The company’s shares closed ye......
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Neurocrine, with a price target of $192.00. The company’s shares ......
News data is sourced from MarketXLS API and updated regularly.
Showing 7 of 7 articles.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NBIX | $141.83 | +2.1% | 967.90K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Neurocrine Biosciences Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW